Navigation Links
Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013
Date:4/23/2013

SEATTLE, April 24, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its first quarter financial results on Thursday, May 2, 2013, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update, at 4:30 p.m. ET (1:30 p.m. PT). Access to the event can be obtained as follows:

Thursday, May 2
1:30 p.m. PT/4:30 p.m. ET/10:30 p.m. CET
1-877-941-6010 (domestic)
+1 480-629-9644 (international)

To access the live audio webcast or the subsequent archived recording, visit CTI's website, www.celltherapeutics.com. Webcast and telephone replays of the conference call will be available at approximately two hours after completion of the call. Callers can access the replay by dialing 1-800-358-3474 (domestic) or +1 303-590-3030 (international). The access code for the replay is #4615670. The telephone replay will be available until Thursday, May 9, 2013.

About Cell Therapeutics, Inc.

Cell Therapeutics (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable. CTI is headquartered in Seattle, WA. For additional information and to sign up for email alerts and get RSS feeds, please visit the company's website at www.CellTherapeutics.com.

Media and Investor Contacts:

Cell Therapeutics, Inc.

Monique Greer
+1 206.272.4343
mgreer@ctiseattle.com

Ed Bell
+1 206.272.4345
invest@ctiseattle.com

In Europe

CTI Life Sciences Limited, Milan Branch

Laura Villa
Elena Bellacicca

E: CTI_EUInvestors@CTI-Lifesciences.com
T: +39 02 89659700
F: +39 02 89659719
http://www.celltherapeutics.com/italiano

 


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
2. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
3. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
4. Resverlogix desincorpora RVX Therapeutics Inc. para sus accionistas
5. Galectin Therapeutics: Turning Atlanta into Americas Next Silicon Valley
6. Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
7. Aratana Therapeutics Adds To Drug Development Team
8. Biovista und DART Therapeutics nehmen Zusammenarbeit auf, um auf Duchenne-Muskeldystrophie abzielende Medikamente neu zu positionieren
9. Novira Therapeutics Completes $25 Million Series A Financing
10. Peptide Therapeutics Market is Expected to Reach USD 25.4 Billion Globally in 2018: Transparency Market Research
11. Pain Therapeutics - Drugs, Markets and Companies - 2013 Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Fla. , Feb. 16, 2017  MDNA ... revolutionizing the development of liquid biopsy tests based ... entered into an exclusive license agreement with its ... MDNA,s proprietary liquid biopsy test for prostate cancer, ... South Korea . This is the first ...
(Date:2/16/2017)... Mass. , Feb. 16, 2017   Biostage, ... the "Company"), a biotechnology company developing bioengineered organ implants ... esophagus, bronchus and trachea, announced today the closing on ... of 20,000,000 shares of common stock and warrants to ... proceeds of $8.0 million. The offering was priced at ...
(Date:2/16/2017)... Feb. 16, 2017  Champions Oncology, Inc. (NASDAQ: ... and sale of advanced technology solutions and products to ... announced the addition of new cohorts of PDX models ... models will expand Champions, product line in hepatocellular cancer, ... cancer, AML, and non-small cell lung cancer (including EGFR ...
(Date:2/16/2017)... and NEW YORK , Feb. ... near completion of their $7M Series B financing, adding ... of the $3.5M led by Mesa Verde Venture Partners ... These resources will be directed towards further accelerating commercial ... a comprehensive genomic profiling test and expanding the Paradigm ...
Breaking Biology Technology:
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, ... clinical-stage immuno-oncology company specializing in the development of ... the treatment of cancer and metastatic disease, announced ... and GMP manufacturing of a second clinical lot ... targeting folate receptor alpha. The manufactured vaccine product ...
(Date:2/2/2017)... Feb. 1, 2017  Central to its deep ... advances worldwide, The Japan Prize Foundation today announced ... have pushed the envelope in their respective fields ... Three scientists are being recognized with the 2017 ... not only contribute to the advancement of science ...
(Date:1/31/2017)...  Spero Therapeutics, LLC, a biopharmaceutical company founded ... bacterial infections, today announced it has acquired a ... Bono Bio Ltd (PBB) to bolster its pipeline ... of Gram-negative bacteria.   The assets acquired have been ... group company. "The acquisition of these ...
Breaking Biology News(10 mins):